

December 31, 2025

Izotropic Announces AGM Results

VANCOUVER, British Columbia, and SACRAMENTO, Calif., December 31, 2025, Izotropic Corporation (CSE: **IZO**) (OTCQB: **IZOZF**) (FSE: **1R3**) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the results of its Annual General and Special Meeting held on December 29, 2025.

Company matters submitted to shareholders for approval as set out in the Company's Notice of Meeting and Management Information Circular, dated November 27, 2025, were approved by the requisite majority of votes cast at the meeting.

The primary annual and special matters acted upon were the approval of all nominees to sit as directors of the corporation for the ensuing year with the number of directors set at five (5), the approval of the re-appointment of auditor Dale Matheson Carr-Hilton LaBonte LLP, and the amendment of the Company's By-Laws to reduce the quorum requirement from 20% to at least 1% of the issued voting shares, with decisions continuing to require majority approval. This amendment was brought forward in response to persistent challenges faced by many public companies, including mail delays, posting disruptions, and delays experienced by shareholders using self-managed trading platforms in receiving voting packages.

The Company thanks all shareholders for their participation and ongoing support.

About Izotropic:

More information about Izotropic Corporation can be found on its corporate website at izocorp.com, its educational website at breastct.com, and by reviewing its profile on SEDAR at sedarplus.ca.

Forward-Looking Statements: This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision,"

"estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale. Podcast episodes are generated with the assistance of Google AI. Content was produced using generative tools and may contain machine-generated elements. Listeners are encouraged to verify all information through official sources.

Contacts:

Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast@izocorp.com

General and Corporate Inquiries
Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.com